Drugs / IPOL
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01346293 | Apr 2011 → May 2013 | diphtheria, measles, pertussis, poliomyelitis +1 | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPOL | “The study was designed to compare the safety and immunogenicity of DTap-IPV with DAPTACEL® + IPOL® as the 5th dose booster” NCT01346293 ↗ |
| Modality | Vaccine | “DAPTACEL® + IPOL® vaccine when administered as the fifth dose booster vaccine” NCT01346293 ↗ |
| Route | Intramuscular | “0.5 mL, Intramuscular (IM) DAPTACEL®; Subcutaneous (SC) MMR®II and VARIVAX®; IM or SC IPOL®” NCT01346293 ↗ |
| Route | Subcutaneous | “0.5 mL, Intramuscular (IM) DAPTACEL®; Subcutaneous (SC) MMR®II and VARIVAX®; IM or SC IPOL®” NCT01346293 ↗ |